16 December 2021 
EMA/CHMP/714788/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Teysuno 
tegafur / gimeracil / oteracil 
On 16 December 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Teysuno. The marketing authorisation holder for this medicinal product is Nordic Group B.V. 
The CHMP adopted a new indication as follows:2 
Teysuno is indicated in adults: 
• 
for the treatment of advanced gastric cancer when given in combination with cisplatin (see 
section 5.1). 
•  as monotherapy or in combination with oxaliplatin or irinotecan, with or without 
bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom 
it is not possible to continue treatment with another fluoropyrimidine due to hand-foot 
syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic 
setting. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text as bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
